Identifying biomarkers for pancreatic cancer
BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?
This study is trying to find new markers in blood samples from people with pancreatic cancer to help doctors detect the disease earlier and improve treatment results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Herlev Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Herlev) |
| Trial ID | NCT03311776 on ClinicalTrials.gov |
What this trial studies
This observational study aims to discover diagnostic, prognostic, and predictive biomarkers for pancreatic cancer (PC) to enhance early detection and treatment outcomes. It involves the prospective collection of biological samples and clinical data from patients diagnosed with PC or suspected malignancy. Participants will provide blood samples before surgery or chemotherapy and during treatment, with follow-ups until disease progression. The goal is to improve the specificity and sensitivity of PC diagnosis and to monitor treatment effectiveness.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with histologically verified pancreatic cancer or those suspected of having it based on clinical and radiological characteristics.
Not a fit: Patients without a confirmed diagnosis of pancreatic cancer or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better treatment strategies for pancreatic cancer patients.
How similar studies have performed: Other studies have explored biomarkers in pancreatic cancer, but this specific approach to early detection and treatment monitoring is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Histologically verified PC (ductal adenocarcinoma) or ampullary adenocarcinoma in a resected specimen; or histopathological confirmation of carcinoma in patients not undergoing surgery in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of PC independently of stage Exclusion Criteria: • None
Where this trial is running
Herlev
- Herlev & Gentofte Hospital — Herlev, Denmark (Recruiting)
Study contacts
- Study coordinator: Julia Sidenius Johansen, MD, DMsc
- Email: Julia.Sidenius.Johansen@regionh.dk
- Phone: +45 38689241
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.